Equity
€181,475 ▲ 8.0%
ISA PHARMA paid out €21,067 in dividends. That is 61% of the 2025 profit.
ISA PHARMA
Lifetime
15 annual accounts with figures on one time axispeak €209,801 (2025)
€209,801▲ 6.2%
lowest -€4,851 (2020)
€34,498▲ 38.9%
peak €181,475 (2025)
€181,475▲ 8.0%
€164,778▲ 15.2%
peak 1.9 FTE (2012)
-not published
Board1 name since 2011
1 director
Documentsfilings and deeds
20-08-202620 days late
2025micro format
Result from €24,829 to €34,498Dividend €21,067Debts from €143,074 to €164,778
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 34,691 companies had the same profile as ISA PHARMA has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,691 companies, not a prediction for ISA PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0835600362
Change of role: , from manager to director
Gazette deed
First establishment
Avenue Albert Drossart 23, Orp-Jauche
Incorporation
published on 29-04-2011 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ISA PHARMA Orp-Jauche | €346,253 | €209,801 | 52.4% | - |
| Pharmacie Bouché & Associés Mont-Saint-Guibert | €362,905 | €187,270 | 5.5% | 1.8 |
| PHARMACIE SCHOONEJANS Sint-Gillis (bij-Brussel) | €392,692 | €195,857 | 10.4% | - |
| Apotheek Herne Pajottegem | €330,199 | €230,519 | 39.4% | 1.8 |
| PHARMACIE VANNESTE Molenbeek-Saint-Jean | €354,066 | €229,255 | 39.2% | 2.7 |
| PHARMANDERLECHT Anderlecht | €304,329 | €231,718 | 43.0% | 3.2 |
| PHARMACIE D'ARENBERG Châtelet | €325,719 | €169,396 | 67.2% | - |
These companies have the same main activity as ISA PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €304,000 and €393,000, founded between 2008 and 2013.
Official details
Source: KBO- Status
- Active since 14-04-2011Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.198.872.9071350 Orp-Jauche, since 18-04-2011
- Financial year end
- 31 December
- Peppol
- Reachable since 22-12-2025
Annual accounts 2025
- ≈ €640,000estimated
- €346,253▲ 11.3%
- Employeeson 31-12-2025
- 5▲ 25.0%
- Filing
- Filed on 20-08-2026
Insights on ISA PHARMA
ISA PHARMA files the micro format. That format states no turnover. The gross margin rose from €163,843 in 2011 to €209,801 in 2025.
The balance sheet grew most in 2012 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ISA PHARMA
- What is the company number of ISA PHARMA?
- The company number of ISA PHARMA is 0835.600.362. The VAT number is the same number with BE in front: BE 0835.600.362.
- Where is ISA PHARMA based?
- The registered office is at Avenue Albert Drossart 23, 1350 Orp-Jauche.Company details
- What does ISA PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of ISA PHARMA?
- ISA PHARMA is a private limited company (BV).
- When was ISA PHARMA founded?
- ISA PHARMA was founded on 14-04-2011.
- Is ISA PHARMA still active?
- Yes, ISA PHARMA is an active enterprise in the KBO register.
- How many employees does ISA PHARMA have?
- ISA PHARMA had an average of 4.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ISA PHARMA fall under?
- In its 2025 annual accounts, ISA PHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of ISA PHARMA?
- The turnover in financial year 2025 is ≈ €640,000. This figure is estimated from the gross margin of €209,801 and 31 comparable companies (NACE 477). It probably lies between €450,000 and €1.2m.
- Is ISA PHARMA profitable?
- In financial year 2025, ISA PHARMA made a profit of €34,498.
- Where can I find the annual accounts of ISA PHARMA?
- ISA PHARMA filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ISA PHARMA due?
- ISA PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.